PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1535795
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1535795
Polycystic Ovarian Syndrome Treatment Market - By Treatment Type (Medications [Drug Class (Oral Contraceptives, Antiandrogen) Distribution Channel], Surgery [Ovarian Wedge Resection, Laparoscopic Ovarian Drilling]) & Global Forecast, 2024 - 2032
Global Polycystic Ovarian Syndrome Treatment Market will show over 5.8% CAGR from 2024 to 2032, driven by increasing prevalence of PCOS globally. Rising awareness about the condition and its complications is prompting more women to seek medical intervention.
The increased healthcare budgets in developed and emerging countries are strengthening access to advanced treatments and diagnostic tools for PCOS. Against this backdrop, in April 2023, Ferring Pharmaceuticals and the BioInnovation Institute (BII) announced a strategic partnership to boost innovation in women's health. This collaboration aims to support and fund early-stage start-ups in reproductive medicine, addressing the underfunding of female-specific conditions.
Further, the augmented investments support medical R&D, leading to better diagnostic tools and more effective treatment options. The improved healthcare infrastructure and greater financial resources contribute to better early detection and management of PCOS, catering to the growing demand for comprehensive treatment solutions.
The overall polycystic ovarian syndrome treatment market is classified based on treatment type and region.
The surgery segment is set for decent growth through 2032, owing to the growing recognition of surgical interventions as effective solutions for severe cases. As non-invasive treatments sometimes fall short, especially for women with significant symptoms or complications, surgical options provide more immediate and tangible relief. The innovations in minimally invasive surgical techniques have improved patient outcomes and recovery times, making surgery a more viable option for PCOS management.
The Selective Estrogen Receptor Modulators (SERMs) drug class medication segment will hold significant industry share by 2032, due to their efficacy in addressing multiple symptoms associated with the condition. SERMs, such as clomiphene citrate, are widely used to induce ovulation in women with PCOS, thus improving fertility outcomes. Their ability to modulate estrogen receptors selectively helps in balancing hormone levels, reducing the risk of endometrial hyperplasia, and alleviating symptoms like irregular menstrual cycles and hirsutism. Moreover, the growing preference for non-invasive and pharmacological treatment options over surgical interventions enhances their appeal.
Europe polycystic ovarian syndrome treatment market size will expand at a notable pace during the forecast period, due to heightened awareness and better diagnostic practices. The increased public health initiatives and educational campaigns have led to greater understanding of PCOS, driving more individuals to seek treatment. Additionally, the healthcare system in the region focuses on improving reproductive health and offers comprehensive care options. The availability of advanced medical technologies and supportive medical policies will facilitate access to effective PCOS treatments across Europe, adding to market value.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising incidence of PCOS among women of reproductive age
- 3.2.1.2 Rising awareness and diagnosis
- 3.2.1.3 Support from government and non-governmental organizations
- 3.2.1.4 Rising incidence of obesity and sedentary lifestyle
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Side effects of medication
- 3.2.2.2 High cost of treatment
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.5 Pipeline analysis
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Medications
- 5.2.1 By drug class
- 5.2.1.1 Oral contraceptives
- 5.2.1.2 Antiandrogen
- 5.2.1.3 Insulin-sensitizing agents
- 5.2.1.4 Antidepressants
- 5.2.1.5 Anti-obesity
- 5.2.1.6 Selective Estrogen Receptor Modulators (SERMs)
- 5.2.1.7 Other drug classes
- 5.2.2 By distribution channel
- 5.2.2.1 Hospital pharmacies
- 5.2.2.2 Retail pharmacies
- 5.2.2.3 Online pharmacies
- 5.2.1 By drug class
- 5.3 Surgery
- 5.3.1 Ovarian wedge resection
- 5.3.2 Laparoscopic ovarian drilling
- 5.3.3 Other surgeries
Chapter 6 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 North America
- 6.2.1 U.S.
- 6.2.2 Canada
- 6.3 Europe
- 6.3.1 Germany
- 6.3.2 UK
- 6.3.3 France
- 6.3.4 Spain
- 6.3.5 Italy
- 6.3.6 Netherlands
- 6.3.7 Rest of Europe
- 6.4 Asia Pacific
- 6.4.1 China
- 6.4.2 Japan
- 6.4.3 India
- 6.4.4 Australia
- 6.4.5 South Korea
- 6.4.6 Rest of Asia Pacific
- 6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Mexico
- 6.5.3 Rest of Latin America
- 6.6 Middle East and Africa
- 6.6.1 South Africa
- 6.6.2 Saudi Arabia
- 6.6.3 UAE
- 6.6.4 Rest of Middle East and Africa
Chapter 7 Company Profiles
- 7.1 Abbott Laboratories
- 7.2 AbbVie Plc
- 7.3 Addex Therapeutics Ltd.
- 7.4 AstraZeneca PLC
- 7.5 Bayer AG
- 7.6 Bristol-Myer Squibb Company
- 7.7 Ferring BV
- 7.8 Johnson and Johnson
- 7.9 Merck KGaA
- 7.10 Mylan N.V
- 7.11 Novartis AG
- 7.12 Pfizer Inc.
- 7.13 Sanofi SA
- 7.14 Takeda Pharmaceutical Company Limited
- 7.15 Teva Pharmaceutical Industries Limited
